Vol. 5 No. 9 (2025)
Reimbursement Recommendations

Risperidone (Longavo)

Published September 2, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Longavo be reimbursed by public drug plans for the treatment of schizophrenia if certain conditions are met.
  • Longavo should only be covered by public drug plans for the treatment of adult patients with schizophrenia.
  • Longavo should only be reimbursed when prescribed by clinicians experienced in using long-acting injectable (LAI) atypical antipsychotic agents to treat adult patients with schizophrenia. Reimbursement for Longavo should follow the same criteria that each public drug plan uses for other LAI atypical antipsychotic agents approved for the condition. Longavo should only be reimbursed if the total cost does not exceed the drug program cost of treatment with the least costly long-acting injectable AAPs for the treatment of schizophrenia.